- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BCYC
Recent news which mentions BCYC
B. Riley Securities Downgrades Rating to Neutral for Bicycle Therapeutics, Lowers Price Target To $33
April 13, 2022
Tickers
BCYC
From Benzinga
From Benzinga
Here's Why Bicycle Therapeutics Stock Looks Ill Today
April 11, 2022
From Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 11, 2022
From Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
April 10, 2022
From Benzinga
Why Bicycle Therapeutics Stock Is Soaring Today
April 08, 2022
From Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
April 08, 2022
From Benzinga
Bicycle Therapeutics's Return On Capital Employed Overview
March 04, 2022
Tickers
BCYC
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
February 14, 2022
From Benzinga
12 biotech stocks to consider buying now as prospects for the sector brighten this year
February 06, 2022
From MarketWatch
Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021
December 17, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
December 09, 2021
From Benzinga
7 A-Rated Biotechs to Buy for the Long Run
December 03, 2021
From InvestorPlace
Looking Into Bicycle Therapeutics's Return On Capital Employed
November 08, 2021
Tickers
BCYC
From Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
October 12, 2021
From Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 08, 2021
From Benzinga
45 Biggest Movers From Yesterday
October 08, 2021
From Benzinga
Bicycle Therapeutics Stock Falls After Interim Data Of Toxin Conjugates In Ovarian Cancer Trial
October 07, 2021
Tickers
BCYC
From Benzinga
From Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 06, 2021
From Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
October 06, 2021
From Benzinga
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
October 03, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
September 30, 2021
From Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
September 17, 2021
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.